search
Back to results

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects

Primary Purpose

Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis

Status
Recruiting
Phase
Phase 1
Locations
Australia
Study Type
Interventional
Intervention
ATH-063
Placebo
Sponsored by
Athos Therapeutics Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Inflammatory Bowel Diseases

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening) or social smoker (smokers with 1-5 cigarettes a week), AND with a negative urine cotinine test at check-in, ≥18 and ≤55 years of age, with BMI >18.5 and <32.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females and a maximum weight of 120 kg. Healthy as defined by: the absence of clinically significant illness and surgery within 4 weeks prior to study drug administration. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease. A history of migraines, childhood asthma, or non-hospitalized depression would not be considered clinically significant. Female participants of non-childbearing potential must be: post-menopausal (spontaneous amenorrhea for at least 12 months prior to dosing) with confirmation by documented follicle-stimulating hormone (FSH) levels ≥ 40 mIU/mL; or surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy, or tubal ligation) at least 3 months prior to dosing. Sexually active females of childbearing potential and non-sterile males must be willing to use an acceptable contraceptive method throughout the study as detailed in section 8.1. Able to understand the study procedures and provide signed informed consent to participate in the study. Exclusion Criteria: Any clinically significant abnormal finding at physical examination. Clinically significant abnormal laboratory test results or positive serology test results for HBsAg, HCV antibody, or HIV antigen and antibody, at screening. Positive pregnancy test or lactating female subject Positive urine drug screen, urine cotinine test, or alcohol breath test (one repeat is allowed). History of significant allergic reactions (e.g., anaphylactic reaction, hypersensitivity, angioedema) to any drug. Clinically significant ECG abnormalities or vital signs abnormalities (systolic BP lower than 90 or over 160 mmHg, diastolic BP lower than 50 or over 95 mmHg, HR less than 45 or over 100 bpm, or RR less than 12 or over 22 bpm) at screening. History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 375 mL of beer 3.5%, 100 mL of wine 13.5%, or 45 mL of distilled alcohol 40%). Low risk level = 10 unites per week for men and women. Use of medications for the timeframes specified below, with the exception of hormonal contraceptives and medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or subject safety (e.g., topical drug products without significant systemic absorption): depot injection or implant within 3 months prior to the first dosing; live attenuated vaccines within 1 month prior to the first dosing; any drug known to induce or inhibit hepatic drug metabolism, including St. John's wort, within 30 days prior to the first dosing; prescription medications within 14 days prior to the first dosing; any other vaccine, including COVID-19 vaccine, within 14 days prior to the first dosing; over-the-counter (OTC) medications and natural health products (including herbal remedies such as, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to the first dosing, with the exception of the occasional use of paracetamol (up to 2 g daily). Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days or 5 x T1/2 whichever is longer prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days or 5 x T1/2 whichever is longer prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to dosing. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Sites / Locations

  • CMAX Clinical ResearchRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Placebo Comparator

Arm Label

SAD cohort

MAD Cohort

Food Effect

SAD cohort (Placebo)

MAD cohort (Placebo)

Arm Description

SAD cohorts 1-4. Subjects in each cohort will be randomized to receive a single oral dose of ATH-063 (capsule) under fasting conditions at the planned dose levels.

MAD cohorts 1-4. Subjects in each cohort will be randomized to receive multiple oral doses of ATH-063 (Capsule) under fasting conditions once daily (QD) for 10 consecutive days at planned dose levels.

An intermediary dose level that has already been administered in this study will be selected for the food-effect evaluation based on the available PK and safety data. This will be conducted under fasting and fed conditions.

SAD cohorts 1-4. Subjects in each cohort will be randomized to receive a single oral dose of placebo (Capsule identical to active ATH-063) under fasting conditions at the planned dose levels.

MAD cohorts 1-4. Subjects in each cohort will be randomized to receive multiple oral doses of placebo (Capsule identical to active ATH-063) under fasting conditions once daily (QD) for 10 consecutive days at planned dose levels.

Outcomes

Primary Outcome Measures

To evaluate the safety and tolerability of ATH-063 following oral administration of single and multiple ascending doses in healthy participants.
Number of participants with serious and other non-serious adverse events

Secondary Outcome Measures

Pharmacokinetic assessment 1
AUC0-t (Area under the plasma concentration-time curve)
Pharmacokinetic assessment 2
AUC0-inf (AUC curve to infinite time)
Pharmacokinetic assessment 3
Cmax (Maximum plasma concentration)
Pharmacokinetic assessment 4
Tmax (Time to maximum plasma concentration (Cmax)
Pharmacokinetic assessment 5
Residual area
Pharmacokinetic assessment 6
T½ el (Half Life)
Pharmacokinetic assessment 7
Kel (Elimination rate constant)
Pharmacokinetic assessment 8
Cl/F (Oral Clearance)
Pharmacokinetic assessment 9
Clss/F (Oral Clearance-steady state)
Pharmacokinetic assessment 10
Vz/F (Apparent volume of distribution)
Pharmacokinetic assessment 11
AUC0-24 (area under the plasma concentration-time curve over the last 24-h dosing interval)
Pharmacokinetic assessment 12
AUC0-tau (area under the curve to the end of the dosing period)
Pharmacokinetic assessment 13
Cmax ss (Maximum plasma concentration at steady state)
Pharmacokinetic assessment 14
Tmax ss (Time to steady state Cmax)
Pharmacokinetic assessment 15
Cmin ss (Minimum drug concentration at steady-state)
Pharmacokinetic assessment 16
Vz ss/F (Apparent volume of distribution at steady state)
Pharmacokinetic assessment 17
Tlag (Lag time)

Full Information

First Posted
March 29, 2023
Last Updated
August 23, 2023
Sponsor
Athos Therapeutics Inc
Collaborators
Syneos Health, Athos Therapeutics Australia Pty Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05807971
Brief Title
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects
Official Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ATH-063 in Healthy Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 6, 2023 (Actual)
Primary Completion Date
November 29, 2023 (Anticipated)
Study Completion Date
January 29, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Athos Therapeutics Inc
Collaborators
Syneos Health, Athos Therapeutics Australia Pty Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to test the ATH-063 drug (single and multiple doses) in Healthy Subjects. The clinical trial aims to evaluate the below. Safety of the drug Tolerability of the drug Pharmacokinetics (PK) (how the human body affects the drug) Pharmacodynamics (PD) (how the drug affects the human body) This will be a single center, Phase 1, First-In-Human, Randomized, Double-Blind (neither the subjects nor the experimenters know which subjects are in the test and control groups), Placebo (a look-alike substance that contains no active drug) - Controlled Study.
Detailed Description
Primary Objective of this study will be to evaluate the safety and tolerability of ATH-063 following oral administration of single and multiple ascending doses (SAD/MAD) in healthy subjects. This is a single center, Phase 1, Randomized, Double-blind, Placebo controlled, sequential SAD/MAD study, with a food-effect arm. The study will be divided into three parts: SAD cohorts MAD cohorts Food-effect (FE) cohort MAD and FE cohorts will be dosed in parallel after the completion of the SAD Cohorts SAD Part: Consist of at least 4 cohorts (1 cohort per dose level). Each cohort will include approximately 8 participants (6 participants receiving the active and 2 participants receiving the placebo). A staggered dosing schedule will be used for dosing of each cohort (under fasting conditions) MAD Part: Consist of up to 4 cohorts (1 cohort per dose level). Each cohort will include approximately 8 participants (6 participants receiving the active and 2 participants receiving the placebo). The cohorts will be dosed sequentially in an ascending fashion. The dose of MAD cohorts is dependent on the available safety, tolerability, and PK data from the SAD part and available safety, tolerability, and PK data from dosed MAD cohorts. Food-effect Part: Approximately twelve (12) participants will be randomized in a 1:1 ratio to one of two treatment sequences (fast-fed/fed-fast) with 6 participants per treatment sequence. The selection of the dose to be administered in the food effect part will depend on the results of the SAD part following the review of safety, tolerability and PK data of the SAD cohorts.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Autoimmune Diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Cohorts (4 each) within the SAD and MAD part will be dosed sequentially in an ascending fashion. MAD cohorts and FE cohort will be dosed in parallel after the completion of the SAD Cohorts.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The study will be double-blinded. The subjects and the clinical personnel involved in the collection, monitoring, revision, or evaluation of AEs, or personnel who could have an impact on the outcome of the study will be blinded with respect to the subject's treatment assignment (ATH-063 or placebo).
Allocation
Randomized
Enrollment
76 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SAD cohort
Arm Type
Experimental
Arm Description
SAD cohorts 1-4. Subjects in each cohort will be randomized to receive a single oral dose of ATH-063 (capsule) under fasting conditions at the planned dose levels.
Arm Title
MAD Cohort
Arm Type
Experimental
Arm Description
MAD cohorts 1-4. Subjects in each cohort will be randomized to receive multiple oral doses of ATH-063 (Capsule) under fasting conditions once daily (QD) for 10 consecutive days at planned dose levels.
Arm Title
Food Effect
Arm Type
Experimental
Arm Description
An intermediary dose level that has already been administered in this study will be selected for the food-effect evaluation based on the available PK and safety data. This will be conducted under fasting and fed conditions.
Arm Title
SAD cohort (Placebo)
Arm Type
Placebo Comparator
Arm Description
SAD cohorts 1-4. Subjects in each cohort will be randomized to receive a single oral dose of placebo (Capsule identical to active ATH-063) under fasting conditions at the planned dose levels.
Arm Title
MAD cohort (Placebo)
Arm Type
Placebo Comparator
Arm Description
MAD cohorts 1-4. Subjects in each cohort will be randomized to receive multiple oral doses of placebo (Capsule identical to active ATH-063) under fasting conditions once daily (QD) for 10 consecutive days at planned dose levels.
Intervention Type
Drug
Intervention Name(s)
ATH-063
Intervention Description
12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Identical capsule to the drug without the active ingredient.
Primary Outcome Measure Information:
Title
To evaluate the safety and tolerability of ATH-063 following oral administration of single and multiple ascending doses in healthy participants.
Description
Number of participants with serious and other non-serious adverse events
Time Frame
SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day
Secondary Outcome Measure Information:
Title
Pharmacokinetic assessment 1
Description
AUC0-t (Area under the plasma concentration-time curve)
Time Frame
SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day
Title
Pharmacokinetic assessment 2
Description
AUC0-inf (AUC curve to infinite time)
Time Frame
SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day
Title
Pharmacokinetic assessment 3
Description
Cmax (Maximum plasma concentration)
Time Frame
SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day
Title
Pharmacokinetic assessment 4
Description
Tmax (Time to maximum plasma concentration (Cmax)
Time Frame
SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day
Title
Pharmacokinetic assessment 5
Description
Residual area
Time Frame
SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day
Title
Pharmacokinetic assessment 6
Description
T½ el (Half Life)
Time Frame
SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day
Title
Pharmacokinetic assessment 7
Description
Kel (Elimination rate constant)
Time Frame
SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day
Title
Pharmacokinetic assessment 8
Description
Cl/F (Oral Clearance)
Time Frame
SAD: Up to 15 ± 1 day, FE: Up to 14 ± 1 day
Title
Pharmacokinetic assessment 9
Description
Clss/F (Oral Clearance-steady state)
Time Frame
MAD: Up to 24 ± 1 day
Title
Pharmacokinetic assessment 10
Description
Vz/F (Apparent volume of distribution)
Time Frame
SAD: Up to 15 ± 1 day, FE: Up to 14 ± 1 day
Title
Pharmacokinetic assessment 11
Description
AUC0-24 (area under the plasma concentration-time curve over the last 24-h dosing interval)
Time Frame
MAD: Up to 24 ± 1 day
Title
Pharmacokinetic assessment 12
Description
AUC0-tau (area under the curve to the end of the dosing period)
Time Frame
MAD: Up to 24 ± 1 day
Title
Pharmacokinetic assessment 13
Description
Cmax ss (Maximum plasma concentration at steady state)
Time Frame
MAD: Up to 24 ± 1 day
Title
Pharmacokinetic assessment 14
Description
Tmax ss (Time to steady state Cmax)
Time Frame
MAD: Up to 24 ± 1 day
Title
Pharmacokinetic assessment 15
Description
Cmin ss (Minimum drug concentration at steady-state)
Time Frame
MAD: Up to 24 ± 1 day
Title
Pharmacokinetic assessment 16
Description
Vz ss/F (Apparent volume of distribution at steady state)
Time Frame
MAD: Up to 24 ± 1 day
Title
Pharmacokinetic assessment 17
Description
Tlag (Lag time)
Time Frame
FE: Up to 14 ± 1 day
Other Pre-specified Outcome Measures:
Title
Pharmacodynamic assessment 1
Description
change from baseline in T-regulatory cells immunophenotype
Time Frame
MAD: Up to 24 ± 1 day
Title
Pharmacodynamic assessment 2
Description
change from baseline in T-regulatory cells H3K9 methylation status
Time Frame
MAD: Up to 24 ± 1 day
Title
Pharmacodynamic assessment 3
Description
change from baseline in plasma proteomic signature
Time Frame
MAD: Up to 24 ± 1 day
Title
Pharmacodynamic assessment 4
Description
change from baseline in stool microbiome signature
Time Frame
MAD: Up to 24 ± 1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening) or social smoker (smokers with 1-5 cigarettes a week), AND with a negative urine cotinine test at check-in, ≥18 and ≤55 years of age, with BMI >18.5 and <32.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females and a maximum weight of 120 kg. Healthy as defined by: the absence of clinically significant illness and surgery within 4 weeks prior to study drug administration. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease. A history of migraines, childhood asthma, or non-hospitalized depression would not be considered clinically significant. Female participants of non-childbearing potential must be: post-menopausal (spontaneous amenorrhea for at least 12 months prior to dosing) with confirmation by documented follicle-stimulating hormone (FSH) levels ≥ 40 mIU/mL; or surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy, or tubal ligation) at least 3 months prior to dosing. Sexually active females of childbearing potential and non-sterile males must be willing to use an acceptable contraceptive method throughout the study as detailed in section 8.1. Able to understand the study procedures and provide signed informed consent to participate in the study. Exclusion Criteria: Any clinically significant abnormal finding at physical examination. Clinically significant abnormal laboratory test results or positive serology test results for HBsAg, HCV antibody, or HIV antigen and antibody, at screening. Positive pregnancy test or lactating female subject Positive urine drug screen, urine cotinine test, or alcohol breath test (one repeat is allowed). History of significant allergic reactions (e.g., anaphylactic reaction, hypersensitivity, angioedema) to any drug. Clinically significant ECG abnormalities or vital signs abnormalities (systolic BP lower than 90 or over 160 mmHg, diastolic BP lower than 50 or over 95 mmHg, HR less than 45 or over 100 bpm, or RR less than 12 or over 22 bpm) at screening. History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 375 mL of beer 3.5%, 100 mL of wine 13.5%, or 45 mL of distilled alcohol 40%). Low risk level = 10 unites per week for men and women. Use of medications for the timeframes specified below, with the exception of hormonal contraceptives and medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or subject safety (e.g., topical drug products without significant systemic absorption): depot injection or implant within 3 months prior to the first dosing; live attenuated vaccines within 1 month prior to the first dosing; any drug known to induce or inhibit hepatic drug metabolism, including St. John's wort, within 30 days prior to the first dosing; prescription medications within 14 days prior to the first dosing; any other vaccine, including COVID-19 vaccine, within 14 days prior to the first dosing; over-the-counter (OTC) medications and natural health products (including herbal remedies such as, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to the first dosing, with the exception of the occasional use of paracetamol (up to 2 g daily). Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days or 5 x T1/2 whichever is longer prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days or 5 x T1/2 whichever is longer prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to dosing. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Briohny Johnston
Phone
08 7088 7900
Email
briohny.johnston@cmax.com.au
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicholas Farinola, B.Sc (Biomed. Sci.),BMBS,FRACP
Organizational Affiliation
CMAX Clinical Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
CMAX Clinical Research
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicholas Farinola, B.Sc(Biomed. Sci.) BMBS,FRACP
Phone
0421570586
Email
Nicholas.farinola@sa.gov.au
First Name & Middle Initial & Last Name & Degree
Nicholas Farinola, B.Sc(Biomed. Sci.) BMBS,FRACP

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects

We'll reach out to this number within 24 hrs